Patent · US Active

Bi-specific fusion proteins

US10858450B2 · kind B2 · utility

4Cited by

21References

7Claims

0Family size

Assignee

Silver Creek Pharmaceuticals, Inc. · US

Inventors

Ulrik Nielsen · Quincy, US
Thomas Wickham · Groton, US
Birgit Schoeberl · Cambridge, US
Brian Harms · Brookline, US
Bryan Linggi · Richland, US
Matthew Onsum · Corona, US
Byron DeLaBarre · Arlington, US

Key dates

Filing date	Apr 19, 2018
Grant date	Dec 8, 2020
Priority date	—
Expiry date	Apr 19, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/80
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.